• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia.

作者信息

Al-Samkari Hanny, Jiang Debbie, Gernsheimer Terry, Liebman Howard, Lee Susie, Bernheisel Chelsea, Wojdyla Matthew, Vredenburg Michael, Cuker Adam

机构信息

Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Harvard Medical School, Boston, Massachusetts, USA.

出版信息

Res Pract Thromb Haemost. 2023 Mar 29;7(3):100134. doi: 10.1016/j.rpth.2023.100134. eCollection 2023 Mar.

DOI:10.1016/j.rpth.2023.100134
PMID:37193124
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10182312/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c517/10182312/c01edc3007f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c517/10182312/c01edc3007f5/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c517/10182312/c01edc3007f5/gr1.jpg

相似文献

1
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia.免疫性血小板减少症患者从艾曲泊帕或罗米司亭转换为阿伐曲泊帕后血小板反应的持久性。
Res Pract Thromb Haemost. 2023 Mar 29;7(3):100134. doi: 10.1016/j.rpth.2023.100134. eCollection 2023 Mar.
2
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.曾接受艾曲泊帕或罗米司亭治疗的成人免疫性血小板减少症患者换用阿伐曲泊帕治疗：一项多中心美国研究。
Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18.
3
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.促血小板生成素受体激动剂（TPO-RAs）：药师在药物类别方面的考虑因素。
Drugs. 2021 Jul;81(11):1285-1305. doi: 10.1007/s40265-021-01553-7. Epub 2021 Jun 23.
4
Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.用于成人免疫性血小板减少症患者的血小板生成素受体激动剂：叙述性综述及间歇性禁食患者的管理方法
Front Cardiovasc Med. 2023 Dec 14;10:1260487. doi: 10.3389/fcvm.2023.1260487. eCollection 2023.
5
Use of eltrombopag after romiplostim in primary immune thrombocytopenia.在原发性免疫性血小板减少症中，在使用罗米司亭后使用艾曲泊帕。
Br J Haematol. 2015 Apr;169(1):111-6. doi: 10.1111/bjh.13266. Epub 2014 Dec 18.
6
Efficacy and Incidence of Treatment-Related Adverse Events of Thrombopoietin Receptor Agonists in Adults with Immune Thrombocytopenia: A Systematic Review and Network Meta-Analysis of Randomized Controlled Study.促血小板生成素受体激动剂治疗成人免疫性血小板减少症的疗效和不良反应发生率：一项随机对照研究的系统评价和网络荟萃分析。
Acta Haematol. 2023;146(3):173-184. doi: 10.1159/000528642. Epub 2022 Dec 26.
7
Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.转换为艾曲泊帕或罗米司亭治疗的慢性免疫性血小板减少症（ITP）患者的治疗模式和临床结局
Int J Hematol. 2015 Mar;101(3):255-63. doi: 10.1007/s12185-014-1731-7. Epub 2015 Jan 14.
8
Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.罗米司亭治疗爱尔兰慢性免疫性血小板减少症的成本效益
Appl Health Econ Health Policy. 2013 Oct;11(5):457-69. doi: 10.1007/s40258-013-0044-y.
9
An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.阿伐曲泊帕治疗慢性免疫性血小板减少症的最新评估。
Expert Rev Clin Immunol. 2022 Aug;18(8):783-791. doi: 10.1080/1744666X.2022.2098119. Epub 2022 Jul 10.
10
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.血小板生成素受体激动剂avatrombopag 的结构、功能和临床应用。
Blood Rev. 2022 May;53:100909. doi: 10.1016/j.blre.2021.100909. Epub 2021 Nov 16.

引用本文的文献

1
A phase 3 study of the efficacy and safety of avatrombopag in Japanese adults with chronic immune thrombocytopenia.一项关于阿伐曲泊帕在日本慢性免疫性血小板减少症成年患者中的疗效和安全性的3期研究。
Int J Hematol. 2025 May 20. doi: 10.1007/s12185-025-04001-4.
2
Safety, efficacy, and treatment satisfaction in adults with ITP who switched to avatrombopag from another TPO-RA.从另一种血小板生成素受体激动剂（TPO-RA）转换为阿伐曲泊帕的免疫性血小板减少症（ITP）成人患者的安全性、疗效及治疗满意度
Blood Adv. 2025 Jun 10;9(11):2733-2743. doi: 10.1182/bloodadvances.2024015635.
3
Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment.

本文引用的文献

1
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.曾接受艾曲泊帕或罗米司亭治疗的成人免疫性血小板减少症患者换用阿伐曲泊帕治疗：一项多中心美国研究。
Br J Haematol. 2022 May;197(3):359-366. doi: 10.1111/bjh.18081. Epub 2022 Feb 18.
2
The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.血小板生成素受体激动剂avatrombopag 的结构、功能和临床应用。
Blood Rev. 2022 May;53:100909. doi: 10.1016/j.blre.2021.100909. Epub 2021 Nov 16.
3
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and Treatment.
化疗引起的血小板减少症：现代诊断与治疗
Br J Haematol. 2025 Apr;206(4):1062-1066. doi: 10.1111/bjh.20037. Epub 2025 Mar 4.
4
Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.基于美国食品药品监督管理局不良事件报告系统的阿伐曲泊帕数据挖掘与安全性分析：一项回顾性药物警戒研究。
Sci Rep. 2024 May 17;14(1):11262. doi: 10.1038/s41598-024-62129-5.
5
Treatment of chemotherapy-induced thrombocytopenia with monotherapy versus combination therapy: the devil is in the details.单药治疗与联合治疗化疗诱导的血小板减少症：细节决定成败。
Res Pract Thromb Haemost. 2023 Nov 4;7(8):102250. doi: 10.1016/j.rpth.2023.102250. eCollection 2023 Nov.
6
Avatrombopag for adults with early versus chronic immune thrombocytopenia.阿伐曲泊帕治疗成人早期与慢性免疫性血小板减少症。
Am J Hematol. 2024 Feb;99(2):155-162. doi: 10.1002/ajh.27080. Epub 2023 Dec 8.
7
Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.促血小板生成素受体激动剂治疗化疗相关性血小板减少症的最佳管理。
Blood Rev. 2024 Jan;63:101139. doi: 10.1016/j.blre.2023.101139. Epub 2023 Oct 18.
8
Proposal for a New Protocol for the Management of Immune Thrombocytopenia (ITP).免疫性血小板减少症（ITP）管理新方案提案
Adv Ther. 2022 Jun;39(6):2287-2291. doi: 10.1007/s12325-022-02133-1. Epub 2022 Apr 7.
成人免疫性血小板减少症：现代诊断与治疗方法。
Semin Thromb Hemost. 2020 Apr;46(3):275-288. doi: 10.1055/s-0039-1700512. Epub 2019 Dec 12.
4
Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.原发性免疫性血小板减少症患者转换血小板生成素受体激动剂治疗
Ther Adv Hematol. 2019 May 9;10:2040620719837906. doi: 10.1177/2040620719837906. eCollection 2019.